Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$94.43 USD

94.43
2,144,649

-3.33 (-3.41%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $94.84 +0.41 (0.43%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance

by Zacks Equity Research

Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.

    Zacks Equity Research

    Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings?

    by Zacks Equity Research

    Illumina (ILMN) might gain from continued growth in Product as well as Service and other segments in the third quarter.

      Zacks Equity Research

      Illumina (ILMN) Strong on Product Launches, Competition Rife

      by Zacks Equity Research

      Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.

        Zacks Equity Research

        Illumina Teams Up With Telegraph Hill to Form Verogen

        by Zacks Equity Research

        Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.

          Zacks Equity Research

          Illumina (ILMN) Rides on New Products, Low Margin a Concern

          by Zacks Equity Research

          Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.

            Zacks Equity Research

            Company News For August 03, 2017

            by Zacks Equity Research

            Companies in the news are: HUM,MDLZ,TWX,ILMN

              Zacks Equity Research

              Illumina (ILMN) Catches Eye: Stock Soars 14.8%

              by Zacks Equity Research

              Illumina (ILMN) was a big mover last session, as the company saw its shares rise over 14% on the day.

                Zacks Equity Research

                Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View

                by Zacks Equity Research

                Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.

                  Zacks Equity Research

                  Can Illumina (ILMN) Spring a Surprise this Earnings Season?

                  by Zacks Equity Research

                  Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.

                    Zacks Equity Research

                    Illumina Offers FDA-Approved NGS Cancer Companion Test Kit

                    by Zacks Equity Research

                    Illumina, Inc. (ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines.

                      Mark Vickery headshot

                      Top Research Reports for Today: CAT, T, LMT and DD

                      by Mark Vickery

                      Today's Research Daily features new research reports on 17 major stocks, including Caterpillar (CAT), AT&T (T), Lockheed Martin (LMT) and DuPont (DD).

                        Zacks Equity Research

                        Illumina (ILMN) Posts In-line Earnings in Q1, Margins Down

                        by Zacks Equity Research

                        Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 64 cents in the first quarter of 2017

                          Zacks Equity Research

                          Should You Sell llumina (ILMN) Before Earnings?

                          by Zacks Equity Research

                          llumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                            Zacks Equity Research

                            Can Illumina (ILMN) Spring a Surprise this Earnings Season?

                            by Zacks Equity Research

                            Illumina Inc. (ILMN), a leading provider of tools and integrated systems for analysis of genetic variation and function, is scheduled to report first-quarter 2017 financial results on Apr 25, after the closing bell.

                              Zacks Equity Research

                              Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe

                              by Zacks Equity Research

                              Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.

                                Mark Vickery headshot

                                Top Research Reports for Today: MSFT, BLK, NOC

                                by Mark Vickery

                                Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), BlackRock (BLK), and Northrop Grumman (NOC).

                                  Sweta Killa headshot

                                  Biotech ETFs Powered by Q4 Earnings

                                  by Sweta Killa

                                  Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

                                    Zacks Equity Research

                                    Illumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017

                                    by Zacks Equity Research

                                    Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 85 cents in the fourth quarter of 2016, which exceeded the Zacks Consensus Estimate by 4.9%.

                                      Zacks Equity Research

                                      Why Illumina (ILMN) Might Surprise This Earnings Season

                                      by Zacks Equity Research

                                      Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                        Zacks Equity Research

                                        IBM Corp (IBM) Beats on Q4 Earnings; FY17 View Positive

                                        by Zacks Equity Research

                                        International Business Machines Corp (IBM) reported fourth-quarter 2016 non-GAAP earnings of $5.01 per share, which increased 3.5% from the year-ago quarter.

                                          Zacks Equity Research

                                          Illumina (ILMN) Q4 Earnings: A Beat in Store for the Stock?

                                          by Zacks Equity Research

                                          We expect Illumina Inc (ILMN) to beat expectations when it reports fourth-quarter 2016 results after the closing bell on Jan 31.

                                            Zacks Equity Research

                                            IBM Watson Commerce Adopted by Ernes to Boost Profitability

                                            by Zacks Equity Research

                                            International Business Machines (IBM) has announced that its cloud-based pricing optimization solution - Watson Commerce - has been selected by the Ermes Group.

                                              Zacks Equity Research

                                              Illumina and Bio-Rad Unveil Single-Cell Sequencing Solution

                                              by Zacks Equity Research

                                              Illumina, Inc. (ILMN) recently teamed up with Bio-Rad Laboratories (BIO) to launch the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference.

                                                Zacks Equity Research

                                                IBM Watson Partners with Illumina to Advance Cancer Research

                                                by Zacks Equity Research

                                                International Business Machines (IBM) owned IBM Watson Health Illumina (ILMN) have inked a partnership to achieve better interpretation of genome data.

                                                  Zacks Equity Research

                                                  Illumina (ILMN) Launches NovaSeq Series for $100 Genome

                                                  by Zacks Equity Research

                                                  Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.